Related by context. All words. (Click for frequent words.) 62 syngeneic 62 oncolytic virus therapies 62 PEGylated interferon 62 receptor tyrosine kinase inhibitor 61 HuMax TAC 61 EliA 61 Safinamide 61 GeneICE 61 Factor VIIa 61 GVAX ® 60 Thiarabine 60 XmAb 60 Omacetaxine 60 Angiocept 60 LymphoStat B TM 60 AAG geldanamycin analog 60 Prodarsan R 60 delivery polymer matrix 60 aldehyde dehydrogenase ALDH2 deficiency 60 Spiegelmer ® 60 interleukin IL -# 60 fusion inhibitor 60 antibody MAb 60 Bayer HealthCare Onyx Pharmaceuticals 60 pharmacokinetic PK study 60 Alfacell proprietary ribonuclease 60 ChronVac C R 60 Neuvenge 60 human IgG1 monoclonal 60 chimeric monoclonal antibody 60 Kahalalide F 60 LEAPS TM 60 CYT# potent vascular disrupting 60 vinorelbine tartrate 60 reslizumab 60 NanoStat 59 accumulate preferentially 59 proprietary electroporation 59 OncoVex 59 Fodosine 59 paclitaxel poliglumex 59 anti CD3 monoclonal 59 hereditary emphysema 59 Xcellerated T Cells 59 PDE4 inhibitor 59 novel therapeutic antibodies 59 phase IIb clinical 59 HCD# [002] 59 huN# DM1 59 LymphoStat B belimumab 59 GRNVAC1 59 colon carcinoma 59 AEG# 59 immunotoxin 59 PF # [002] 59 DEB# 59 Gentamicin Surgical Implant 59 Silodosin 59 OvaRex R 59 RhuDex ® 59 PNP inhibitor 59 Annamycin 59 lead Aganocide compound 58 NPC 1C 58 GHRH 58 humanised monoclonal antibody 58 oral prodrug 58 cathepsin K inhibitor 58 Guanilib 58 Gleevec resistant 58 targeted radiotherapeutic 58 Monoclonal antibody 58 ChronVac C ® 58 FELV 58 TLK# 58 Sphingomab TM 58 investigational HCV polymerase 58 LBH# 58 Sudhir Agrawal D.Phil 58 2A receptor agonist 58 PSMA ADC 58 intranasal formulation 58 isavuconazole 58 mertansine 58 generation purine nucleoside 58 Olaparib 58 randomized controlled Phase 58 Lpathomab 58 Valtropin 58 Alferon N 58 Xanafide 58 NOD mouse 58 multicenter Phase II 58 recombinant PSMA vaccine 58 Allovectin 7 58 TELINTRA R 58 chimeric antibody 58 anti CD3 antibody 58 MKC# MT 58 Micromet BiTE 58 vivo validation 58 immunotherapeutic vaccine 58 Onconase 58 multicenter phase 58 BiTE R 58 MAGE A3 ASCI 58 small molecule tyrosine 58 vapreotide acetate 58 MVA MUC1 IL2 58 including eniluracil ADH 58 Phase IIb clinical trials 58 MMP inhibitor 58 1 Proteinase Inhibitor 57 potent cytotoxic 57 Quinamed 57 IMA# 57 phase IIb III 57 Phase #b/#a clinical 57 Gleevec imatinib mesylate 57 HepaMate 57 generation antisense inhibitor 57 Phase IIb trials 57 vidofludimus 57 multiple myeloma MM 57 initiated Phase Ib 57 investigational protease inhibitor 57 DepoVax TM 57 Phase 1b clinical trials 57 targeted antifolate 57 MEK inhibitor 57 phase Ib clinical 57 metabotropic glutamate receptors 57 hypoxia activated prodrug 57 orally dosed 57 bortezomib Velcade 57 Capesaris 57 Ostabolin C TM 57 systemic RNAi therapeutic 57 lipopeptide 57 Degarelix 57 assessing T DM1 57 Lodamin 57 ESBA# 57 CCR9 antagonist 57 acyclovir Lauriad R 57 Fludara ® 57 gamma secretase inhibitor 57 Imatinib mesylate 57 phase IIb study 57 plasmid DNA pDNA 57 aurora kinase 57 AERx ® 57 AFREZZA TM 57 tolevamer 57 Kamada AAT 57 delta opioid receptor 57 beta 1a 57 RhuDex R 57 Dapagliflozin 57 phase IIa 57 humanised antibody 57 Simulect 57 adrenoceptor agonist 57 PEG IFN 57 receptor inhibitor 57 multicenter Phase 57 nucleotide analog 57 CRLX# 57 5alpha reductase 57 preclinical efficacy 57 platinum chemotherapeutic 57 ReN# 57 Zalypsis 57 HGS# 57 pentostatin 57 Mipomersen 57 introduced NEUGENE 57 trastuzumab DM1 T DM1 57 MKC# MKC# PP 57 SinuNase ™ 57 iobenguane 57 PORxin TM platforms 57 DXL# 57 Topoisomerase II 57 topical gel formulation 57 HepDirect prodrug 57 CytoFabTM 57 Panzem 57 AmpliChip 57 recombinant polyclonal antibodies 57 liposomal delivery 57 oral ghrelin agonist 57 miconazole Lauriad ® 57 Prodarsan ® 57 Trastuzumab DM1 57 ImmunoGen TAP technology 57 CAPHOSOL R 57 TMC# C# 57 Proxinium TM 57 phase Ib 56 liposomal formulation 56 immunotherapeutic agent 56 Alocrest 56 TransVax 56 Pharmacokinetics PK 56 torezolid 56 Cand5 56 DermaVir 56 rALLy clinical trial 56 HuMax CD#b 56 fosbretabulin 56 PANVAC VF 56 NASDAQ CGEN announced 56 IIa clinical trials 56 Chronic lymphocytic leukemia CLL 56 M1 muscarinic 56 cGMP manufacture 56 using Crucell PER.C6 56 selective A2A adenosine receptor 56 lutropin alfa 56 Oxycyte TM 56 RAV# 56 Personalized Immunotherapy 56 TLR9 agonist 56 Aplidin 56 AKT inhibitor 56 metastatic malignant 56 selective orally bioavailable 56 nilotinib Tasigna 56 Pancreate 56 orally inhaled migraine 56 vivo electroporation 56 Cyclosporin 56 novel nucleoside analog 56 nasal decolonization 56 Lactoferrin 56 randomized multicenter trial 56 samalizumab 56 A1PI 56 Inotek Pharmaceuticals Corporation 56 potently inhibit 56 dasatinib Sprycel 56 Tarvacin TM 56 OncoVEX 56 Tarvacin Anti Cancer 56 ADVIA Centaur 56 anti CD3 56 SynCon 56 OncoGel 56 VitiGam 56 Initiate Phase 56 IIa trial 56 GLP toxicology studies 56 PEGylated 56 non nucleoside inhibitor 56 cyclin dependent kinase inhibitor 56 Fc fusion protein 56 ProImmune 56 anionic backbone 56 antitrypsin 56 Cogane 56 WX UK1 56 lentiviral vector 56 xenograft model 56 1 antitrypsin 56 CBLC# 56 INS# [001] 56 anti angiogenic agent 56 LHRH antagonist 56 vaccine ChronVac C 56 OMP #M# 56 proteasome inhibitor 56 small molecule glucokinase 56 IMiD 56 Temsirolimus 56 LAB CGRP 56 evaluating tivozanib 56 phosphatidylserine PS targeting 56 GLPG# 56 intradermal delivery 56 GRN# 56 Zybrestat 56 taxane derivative 56 neuronal nicotinic receptor NNR 56 Neugene 56 Aflibercept 56 Onalta ™ 56 experimental autoimmune encephalomyelitis 56 Atripla combines 56 volociximab 56 OHR/AVR# 56 Fibrin MB 56 ketolide antibiotic 56 Initiated Phase 56 novel peptide 56 Novolimus 56 Aganocide 56 TBC M4 56 Fenretinide 55 cellular immunotherapy 55 eligen 55 DCVax 55 budesonide MMX Phase III 55 Vidofludimus 55 proprietary chemically modified 55 Cloretazine ® 55 NS5B polymerase 55 lumiliximab 55 Ceflatonin 55 hormone LHRH antagonist 55 novel immunotherapeutic 55 Archexin 55 kallikrein 55 PI3K inhibitor 55 Nanobody 55 Dr. Gabriel Lasala 55 sitaxsentan 55 omega interferon 55 cartilage regeneration 55 Phase Ib IIa 55 cannabinor 55 Ketotransdel 55 Oglemilast 55 rhFVIIa 55 glucokinase activator 55 humanized therapeutic 55 Proellex TM 55 Bosutinib 55 morpholino 55 TransVax tm 55 Vaxfectin R formulated 55 BRIM2 55 immuno therapeutic 55 Telatinib 55 Curaxin CBLC# 55 THR beta agonist 55 Phase Ib clinical trials 55 MT#/MEDI-# 55 Pruvel TM 55 Erimos 55 controlled multicenter Phase 55 1 antitrypsin AAT 55 JAK inhibitor 55 INxin TM 55 Neo Bladder Augment 55 HuMax CD4 55 Veronate R 55 Phase Ib study 55 tiapamil 55 flavopiridol 55 Tykerb lapatinib 55 tumor antigen 55 CYT# QbG# 55 Kevetrin ™ 55 Phase Ib II 55 Aurograb 55 virus HCV protease inhibitor 55 next generation URAT1 55 GeoVax vaccine 55 SCIB1 55 antisense drug 55 vivo preclinical 55 PORxin TM 55 novel VDA molecule 55 P#X# antagonist 55 Immunotherapeutic 55 Qutenza TM 55 phase IIb trial 55 GTC recombinant form 55 CA9 SCAN 55 Syncria albiglutide 55 NV1FGF 55 ocular formulation 55 EC Cysteamine 55 RhuDex 55 ELISPOT assay 55 porcine derived 55 BEZ# 55 II Clinical Trial 55 non nucleoside 55 5 fluorouracil leucovorin 55 registrational Phase 55 canine heartworm 55 VersaFilm 55 Oxford Immunotec 55 LB# [003] 55 JAK2 inhibitor 55 fibrin derived 55 PEGylated anti 55 VIR# 55 Anavex #-# 55 adecatumumab MT# 55 inhaled AAT 55 Dasatinib 55 Phase IIA 55 RE COVER 55 cancer immunotherapies 55 Liposomal 55 alvespimycin 55 Phase IIb Trial 55 Litx 55 PI3K/Akt pathway inhibitor 55 HQK 55 reverse vaccinology 55 huC# DM4 55 acadesine 55 Protexia ® 55 nucleoside analog 55 Omnitarg 55 recombinant antibodies 55 forodesine 55 hyaluronidase enzyme 55 treat chronic sinusitis 55 Oncotype DX colon cancer 55 feline leukemia virus 55 Phase IIIb clinical 55 receptor blocker 55 bispecific 55 JAK3 inhibitor 54 buccal delivery 54 HER2 ErbB2 54 calcitonin gene related 54 lipid nanoparticle 54 antiangiogenic agent 54 transmucosal delivery system 54 Prodarsan 54 HuMax CD# 54 Vitaxin 54 Humanized Anti 54 vemurafenib 54 Phase #/#a 54 ospemifene 54 REGEN trial 54 Clolar ® 54 Phase Ib clinical 54 selectively inhibited 54 phase IIa clinical 54 RhuDex TM 54 Curaxin 54 ALN TTR# 54 PrevOnco ™ 54 selectively binds 54 Denufosol 54 HuMax EGFr 54 Solulin 54 confirmatory clinical 54 SynCon TM 54 ZK EPO 54 SensiGene 54 ALN PCS 54 Phase III confirmatory 54 photoprotective drug 54 2DG 54 ONCONASE R 54 cyclophilin inhibitors 54 depsipeptide 54 glycogen synthase kinase 54 Alpha1 Proteinase Inhibitor 54 ALVESCO R 54 SAR# [004] 54 Histone deacetylase 54 HCV RNA polymerase 54 trial evaluating PRX# 54 Phase 1a clinical 54 EDEMA3 54 multi kinase inhibitor 54 PDE# inhibitors 54 triphendiol 54 randomized Phase IIb 54 RONDEL ™ 54 mGluR2 positive 54 Anti VEGF 54 sterile lidocaine patch 54 Annexin V 54 ProSavin 54 prostate carcinoma 54 Plicera 54 Hedgehog antagonist 54 acyclovir Lauriad ® 54 NEUGENE R 54 systemic anaplastic large 54 TEMSO 54 Corlux 54 selective androgen receptor modulator 54 Phase IIb III 54 GeneSightRx 54 therapeutic monoclonal antibody 54 interstitial cystitis IC 54 SinuNase TM 54 Taenia 54 HuMax Inflam 54 successfully commercialize Iluvien 54 Nexavar sorafenib 54 oral methylnaltrexone 54 Exherin TM 54 IND submission 54 multicenter randomized placebo controlled 54 KL4 Surfactant 54 Pimavanserin 54 tubulin inhibitor 54 EGS# 54 Phase 1b trial 54 BHT DNA 54 radiolabeled TM# 54 oral rivaroxaban 54 bispecific antibody 54 octreotide implant 54 Ophena 54 romazarit 54 Cannabinor 54 Aganocide ® 54 Locked Nucleic Acid LNA 54 pediatric acute lymphoblastic 54 Oral NKTR 54 peptidomimetic 54 PSN# [002] 54 PENNVAX B 54 ACE BioSciences 54 Fleximer R 54 Cx# [002] 54 riociguat 54 receptor antagonism 54 lipid particle 54 BRAF inhibitor 54 2A agonist 54 Crucell genetically engineered 54 International SMI SYNN 54 Enkephalin 54 autoimmune encephalitis 54 nucleotide analogue 54 Achieves Primary Endpoint 54 SPL# Gel vaginal microbicide 54 Initiates Enrollment 54 ATPace TM 54 IL-#/# 54 selective agonist 54 biliary tract cancer 54 BrachySil TM 54 Solazed 54 alkylating agent 54 SIV infected 54 AsepticSure 54 NXL# 54 C#BL 6 mice 54 CRD5 54 cetrorelix pamoate 54 Dacogen decitabine 54 pivotal bioequivalence 54 BNC# 54 SIX RO ROG 54 5HT 54 UPLYSO 54 Intravenous immunoglobulin 54 HepaLife PICM 54 Provectus Pharmaceuticals specializes 54 p# MAPK 54 optimal dosing regimens 54 Hypoxia Inducible Factor 54 perfluorocarbon PFC therapeutic 54 Troxatyl 54 YONDELIS 54 GRNCM1 54 TBC# 54 PhG alpha 1 53 transcutaneous immunization TCI 53 BLP# 53 reversible inhibitor 53 Phase 2a clinical 53 budesonide foam 53 ORACLE MS 53 IIa trials 53 LungAlert TM 53 oral Janus kinase 53 Secretase 53 ORMD 53 RELOVAIR ™ 53 Argatroban 53 imetelstat GRN#L 53 docetaxel Taxotere R 53 SGLT2 inhibitors 53 ribonuclease 53 GLP1 agonist 53 SUCCEED trial 53 Î ² 53 pipeline ImmunoGen collaborators 53 FLT3 53 acetonide FA 53 nanoviricide 53 FTIs 53 defensin mimetic antibiotic 53 ulimorelin 53 afamelanotide 53 targeting CD# 53 SEPET TM 53 chemokine receptor 53 antisense therapies 53 registrational trial 53 IIb clinical trial 53 initiate multicenter 53 StemEx 53 procollagen 53 enzyme inhibitor 53 Imvamune R 53 dexpramipexole 53 RezularTM 53 exon skipping 53 chronic eosinophilic leukemia 53 Empatic ™ 53 DiabeCell 53 systemic RNAi 53 NP2 53 canagliflozin 53 Ceragenin ™ 53 ACV1 53 potent suppressor 53 Lovaxin C 53 overactive bladder AA# 53 miglustat 53 DermaVir Patch 53 Vaxfectin TM formulated 53 Peroxisome Proliferator Activated Receptor 53 human secretin 53 CVac 53 transgenic mouse models 53 multitargeted 53 synthetic peptide containing 53 Hedgehog pathway inhibitor 53 Vaxfectin ® 53 inhaled formulation 53 Evoltra ® 53 cilengitide 53 immatics 53 lomitapide 53 midstage trials 53 glucosidase 53 CMV vaccine 53 virotherapy 53 xenograft mouse 53 SAR# [002] 53 ofatumumab HuMax CD# 53 Phase 1b clinical 53 genetically reprogrammed 53 glyco 53 immunomodulator 53 ALK inhibitors 53 dimebon latrepirdine 53 delipidation 53 RiVax 53 ADVANCE PD 53 phosphatidylserine PS 53 elacytarabine 53 laninamivir 53 Tarceva TM 53 BRIM3 53 ATL# [001] 53 NADiA 53 Aerosurf 53 immunoglobulin Ig 53 Crizotinib 53 gonadotropin releasing hormone GnRH 53 midstage clinical 53 antisense inhibition 53 Deforolimus 53 Phase IIa proof 53 ZFP Therapeutic 53 rPA anthrax vaccine 53 Traficet EN 53 myeloid lineage 53 Inhaled nitric oxide 53 ENABLE Phase 2 53 PHX# 53 dose escalation clinical 53 anticancer therapeutics 53 HDL Selective Delipidation 53 Tumor necrosis factor 53 multicenter dose escalation 53 Lucanix 53 farletuzumab 53 tramiprosate Alzhemed TM 53 Zysolin TM 53 Dalbavancin 53 OvaRex MAb 53 nasally administered 53 Transdrug R 53 investigational antibiotic 53 bardoxolone 53 Urocidin 53 BCR ABL inhibitor 53 Feline Leukemia 53 developing Bicifadine serotonin 53 somatostatin 53 CHAMPION PCI 53 IMiDs ® 53 Parkinson disease levodopa induced 53 Aeolus Pharmaceuticals Announces 53 IIIA NSCLC 53 Removab 53 MoxDuo ® 53 kappa B 53 nicotinic acetylcholine receptor 53 triiodothyronine 53 candidates Azedra TM 53 Memgen 53 Zenvia ™ 53 phosphoprotein 53 vitro toxicology 53 MT# MEDI 53 fluorinated carbohydrate mimics 53 MabThera rituximab 53 indibulin 53 Antisoma AS# 53 Biopharmaceuticals AG 53 Phase 2b Clinical Trial 53 embryoid body 53 Apatone 53 1 proteinase inhibitor 53 Xelox 53 oral ridaforolimus 53 adenoviral conjunctivitis 53 antimitotic 53 PARI Pharma GmbH 52 Fx #A 52 Vacc 4x 52 receptor antagonists 52 ProtAffin 52 PTK# 52 GALNS 52 Daclizumab 52 Phase IIa trial 52 Protein Kinase C 52 PD LID 52 Multiple Ascending Dose 52 phase IIIb 52 integrase inhibitor 52 Alequel ™ 52 personalized cellular immunotherapy 52 molecular diagnostic assay 52 treatment naive genotype 52 TRO# 52 OTCQX RHHBY 52 translational genomics 52 renin inhibitor 52 Testosterone MDTS ® 52 Phase IIa clinical 52 Panzem R NCD 52 catheter occlusion 52 patented Modular Cartridge 52 Valproic acid 52 Elagolix 52 Alexza Staccato 52 Testosterone MDTS R 52 Novasome R 52 ELISA assay 52 IL# PE#QQR 52 GVAX R 52 Roflumilast 52 p# inhibitor 52 CG# [003] 52 TACI Ig 52 gonadotrophin releasing hormone 52 pegylated IFN 52 ursodiol 52 lucinactant 52 ACAPODENE TM 52 DPX Survivac 52 davalintide 52 Anticalins R 52 pegylated 52 Iloperidone 52 Tumour Necrosis Factor 52 antibiotic amikacin 52 allosteric modulator NAM 52 dyskinesia PD LID 52 Phase 2a trial 52 Almorexant 52 Talotrexin 52 isoenzyme 52 adrenergic regulation 52 Tolamba 52 resminostat 52 Hedgehog agonist 52 murine models 52 OvaRex ® MAb 52 loaded dendritic cell 52 TransMID 52 vitro experiments 52 antisense inhibitor 52 omacetaxine mepesuccinate 52 intra arterial chemotherapy 52 SinoFresh Nasal Spray 52 RE MODEL 52 rindopepimut 52 preclinical toxicology 52 Overexpression 52 radezolid 52 Pertuzumab 52 hapten 52 C#BL 6 52 transdermal gel 52 Resurgex Plus R 52 Kibow 52 immunostaining 52 MoxDuo R 52 Lodotra TM 52 lorvotuzumab mertansine 52 Cardio Vascu Grow 52 Perceiva 52 cortisol synthesis 52 Sphingomab 52 gag pol 52 cytokine refractory 52 masitinib 52 preclinically 52 lentiviral 52 GSK# [002] 52 protein receptors lectins 52 phase IIb 52 antisense oligonucleotide 52 Ozarelix 52 TFChem licenses 52 prostone 52 R#/MEM # 52 massively parallel sequencing 52 experimentally infected 52 oral salmon calcitonin 52 CDAD Clostridium difficile 52 interferon beta 1b 52 Ocrelizumab 52 JAK inhibitors 52 nitric oxide donating prostaglandin 52 Tocosol Paclitaxel 52 thapsigargin 52 PrevOnco 52 investigational humanized monoclonal antibody 52 Sym# 52 Vernakalant 52 COPEGUS therapy 52 allogeneic cell 52 Febit 52 chimeric protein 52 clinical trials Archexin 52 adenovirus serotype 52 leading oral taxane 52 trodusquemine 52 Amplimexon 52 Lucanix R 52 Sipuleucel T 52 trastuzumab DM1 52 Virulizin ® 52 YONDELIS R 52 Adrenergic 52 pDNA vaccines 52 AVEO integrates proprietary 52 methylnaltrexone bromide 52 HepDirect R 52 adrenoceptor 52 Trandolapril 52 chimeric antibodies 52 developed preclinically 52 staphylococcal vaccine 52 incyclinide 52 Oragene • 52 ToGA 52 integrin alpha 52 automated radiopharmaceutical distribution 52 mTOR inhibitor 52 baminercept 52 CCR5 inhibitor 52 MDCK 52 effector function 52 NS5A inhibitor 52 Ovonic fuel 52 quinoline 52 Randomized Phase 52 hGH CTP Phase 52 selective adenosine 52 BiTE 52 M Vax 52 telomerase activator 52 AGE Crosslink Breaker 52 CD# antibody [001] 52 GLP1 INT TM 52 #I TM# 52 angiogenesis inhibitor 52 TransVax ™ 52 Initiates Clinical Trials 52 subcutaneously administered 52 Vaxart 52 Tesetaxel 52 pafuramidine maleate 52 TriGrid 52 Altera Nebulizer System 52 Multimeric 52 ABSORB clinical 52 MyoCell SDF 1 52 Dermylex TM 52 PN# [001] 52 Phase IIb clinical 52 alpha2 52 REVIVE Diabetes 52 Phase #b/#a trial 52 Anacetrapib 52 IIa clinical 52 Kevetrin TM 52 azilsartan medoxomil 52 Pivotal Study 52 Onalta 52 P#X# 52 GAMMAGARD 52 bioengineered tissue 52 class mGluR5 inhibitor 52 Memryte 52 Xerecept 52 IIa clinical trial 52 OMP #R# 52 activin 52 gB 52 TSX VENTURE COT 51 protein biochip 51 CML CP 51 aspartyl 51 QNEXA ® 51 bipolar wafer 51 tremelimumab 51 Diamyd ® 51 JZP 51 basal insulin analogue 51 Sorafenib Nexavar 51 generation URAT1 inhibitor 51 lamivudine resistant 51 anticancer compound 51 antigenic epitopes 51 molecular imaging radiopharmaceutical 51 Bezielle 51 antiangiogenesis 51 colony stimulating factor 51 cortisol receptor 51 maturation inhibitor 51 EndoTAG TM -1 51 constitutively active 51 multiplexed assays 51 Tubulin 51 Vertex hepatitis C 51 LC MALDI 51 myoblast 51 hyperinsulinemic euglycemic clamp 51 clinic automation LabPas 51 include ColorectAlert TM 51 evaluating satraplatin 51 OSI Tarceva 51 GelSite polymer 51 evaluating satraplatin plus 51 histone deacetylase inhibitors 51 EndoTAG TM 51 TRX1 51 glutamyl 51 enzymatic reactions immunodiagnostics 51 muscarinic 51 iPSC 51 Surface Plasmon Resonance SPR 51 protein electrophoresis 51 Sanofi aventis EURONEXT SAN 51 CRMD# 51 Tr DNA 51 LUX Lung 51 BioFocus DPI Galapagos 51 evaluating mipomersen 51 PSN# [001] 51 sorafenib Nexavar 51 Dacogen injection 51 HemoGenix 51 CELVAPAN H#N# 51 ketoprofen patch 51 SUPER PET 51 defensin 51 MVA BN 51 alemtuzumab Campath 51 β1 51 receptor activator 51 exendin 4 51 IMC #B 51 Excellarate TM 51 Selective Inhibitor 51 cyclic nucleotide 51 OncoVEX GM CSF 51 XmAb# 51 Vaxfectin 51 riboflavin vitamin B2 51 Vitro Diagnostic IVD 51 Luramist 51 Phase IIa trials 51 BRAF inhibitors 51 Squalamine 51 oral anticancer 51 QuantiFERON 51 TLR agonists 51 Panzem R 51 CB2 selective receptor agonist 51 oglemilast